Global Multi-Dose Medication Market
Global Multi-Dose Medication Market

Multi-Dose Medication Comprehensive Study by End-users (Hospitals & Clinics, Pharmacies, Others), Software (Computerized Physician Order Entry, Clinical Decision Support System, Automated Dispensing Systems, Others) Players and Region - Global Market Outlook to 2027

Multi-Dose Medication Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

May 2022 Edition 233 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Multi-Dose Medication?
Multi-dose medicinal drugs are labelled as such by way of the manufacturer and commonly incorporate an antimicrobial preservative to assist stop the increase of bacteria. The preservative has no impact on viruses and does no longer guard towards infection when healthcare personnel fail to observe secure injection practices. Multi-dose is a choice to regular prescription dishing out for human beings with ordinary medicinal drug use blended with difficulties in managing and administering their drugs. Multi-dose users can also be greater uncovered to probably inappropriate drug use than normal prescription users.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledOmnicell (United States), Epic Systems Corporation (Wisconsin), BD (United States), Cerner Corporation (United States), McKesson Corporation (United States), UnitedHealth Group (United States), ARxIUM (Canada), Cureatr (United States), DrFirst (United States) and GE Healthcare (United States)
CAGR%


The market study is broken down and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Multi-Dose Medication market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Omnicell (United States), Epic Systems Corporation (Wisconsin), BD (United States), Cerner Corporation (United States), McKesson Corporation (United States), UnitedHealth Group (United States), ARxIUM (Canada), Cureatr (United States), DrFirst (United States) and GE Healthcare (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Genoa (United States), Healthcom (United States) and ICU Medical (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Multi-Dose Medication market by Type, Application and Region.

On the basis of geography, the market of Multi-Dose Medication has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Hospitals & Clinics will boost the Multi-Dose Medication market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Software, the sub-segment i.e. Computerized Physician Order Entry will boost the Multi-Dose Medication market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, Cardinal Health launched Cardinal Health NavixRxTM Compliance Packaging, which affords unbiased pharmacies with an answer to outsource compliance packaging for sufferers taking two or extra prescriptions daily. Furthermore, the packaging facility is absolutely operational in Lewisville with proximity to a Cardinal Health distribution middle and the Dallas Fort Worth and Alliance airports, presenting furnish and logistical blessings for provider to pharmacies nationwide.
The legislation of capsules varies through jurisdiction. In some countries, such as the United States, they are regulated at the country wide degree by way of a single agency. In different jurisdictions, they are regulated at the kingdom level, or at each country and country wide degrees through a number of bodies, as is the case in Australia. The position of therapeutic items law is designed by and large to defend the fitness and protection of the population. Regulation is aimed at ensuring the safety, quality, and efficacy of the therapeutic items which are blanketed underneath the scope of the regulation. In most jurisdictions, therapeutic items should be registered earlier than they are allowed to be marketed. There is generally some diploma of restrict of the availability of positive therapeutic items relying on their hazard to consumers.

Market Trend
  • E-Medication & Electronic Medication Management
  • Reduction in Medication Errors & Healthcare Costs

Market Drivers
  • Growth in the Awareness about the Benefits of Proper Medication to the Consumers

Opportunities
  • Increased in Healthcare Expenditure


Challenges
  • High Installation and Maintenance Costs of Automated Systems
  • Lack of Awareness Regarding multi-dose Medication


Key Target Audience
Multi-Dose Medication Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Omnicell (United States), Epic Systems Corporation (Wisconsin), BD (United States), Cerner Corporation (United States), McKesson Corporation (United States), UnitedHealth Group (United States), ARxIUM (Canada), Cureatr (United States), DrFirst (United States) and GE Healthcare (United States) etc.

2. Can we have customized study for Multi-Dose Medication Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Multi-Dose Medication Market by 2027?
Analysts at AMA estimates Multi-Dose Medication Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By End-users
  • Hospitals & Clinics
  • Pharmacies
  • Others

By Software
  • Computerized Physician Order Entry
  • Clinical Decision Support System
  • Automated Dispensing Systems
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in the Awareness about the Benefits of Proper Medication to the Consumers
    • 3.3. Market Challenges
      • 3.3.1. High Installation and Maintenance Costs of Automated Systems
      • 3.3.2. Lack of Awareness Regarding multi-dose Medication
    • 3.4. Market Trends
      • 3.4.1. E-Medication & Electronic Medication Management
      • 3.4.2. Reduction in Medication Errors & Healthcare Costs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Multi-Dose Medication, by End-users, Software and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Multi-Dose Medication (Value)
      • 5.2.1. Global Multi-Dose Medication by: End-users (Value)
        • 5.2.1.1. Hospitals & Clinics
        • 5.2.1.2. Pharmacies
        • 5.2.1.3. Others
      • 5.2.2. Global Multi-Dose Medication by: Software (Value)
        • 5.2.2.1. Computerized Physician Order Entry
        • 5.2.2.2. Clinical Decision Support System
        • 5.2.2.3. Automated Dispensing Systems
        • 5.2.2.4. Others
      • 5.2.3. Global Multi-Dose Medication Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Multi-Dose Medication: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Omnicell (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Epic Systems Corporation (Wisconsin)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BD (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cerner Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. McKesson Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. UnitedHealth Group (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ARxIUM (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cureatr (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DrFirst (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GE Healthcare (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Multi-Dose Medication Sale, by End-users, Software and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Multi-Dose Medication (Value)
      • 7.2.1. Global Multi-Dose Medication by: End-users (Value)
        • 7.2.1.1. Hospitals & Clinics
        • 7.2.1.2. Pharmacies
        • 7.2.1.3. Others
      • 7.2.2. Global Multi-Dose Medication by: Software (Value)
        • 7.2.2.1. Computerized Physician Order Entry
        • 7.2.2.2. Clinical Decision Support System
        • 7.2.2.3. Automated Dispensing Systems
        • 7.2.2.4. Others
      • 7.2.3. Global Multi-Dose Medication Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Multi-Dose Medication: by End-users(USD Million)
  • Table 2. Multi-Dose Medication Hospitals & Clinics , by Region USD Million (2016-2021)
  • Table 3. Multi-Dose Medication Pharmacies , by Region USD Million (2016-2021)
  • Table 4. Multi-Dose Medication Others , by Region USD Million (2016-2021)
  • Table 5. Multi-Dose Medication: by Software(USD Million)
  • Table 6. Multi-Dose Medication Computerized Physician Order Entry , by Region USD Million (2016-2021)
  • Table 7. Multi-Dose Medication Clinical Decision Support System , by Region USD Million (2016-2021)
  • Table 8. Multi-Dose Medication Automated Dispensing Systems , by Region USD Million (2016-2021)
  • Table 9. Multi-Dose Medication Others , by Region USD Million (2016-2021)
  • Table 10. South America Multi-Dose Medication, by Country USD Million (2016-2021)
  • Table 11. South America Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 12. South America Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 13. Brazil Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 14. Brazil Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 15. Argentina Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 16. Argentina Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 17. Rest of South America Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 18. Rest of South America Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 19. Asia Pacific Multi-Dose Medication, by Country USD Million (2016-2021)
  • Table 20. Asia Pacific Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 21. Asia Pacific Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 22. China Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 23. China Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 24. Japan Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 25. Japan Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 26. India Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 27. India Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 28. South Korea Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 29. South Korea Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 30. Australia Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 31. Australia Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 32. Rest of Asia-Pacific Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 33. Rest of Asia-Pacific Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 34. Europe Multi-Dose Medication, by Country USD Million (2016-2021)
  • Table 35. Europe Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 36. Europe Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 37. Germany Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 38. Germany Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 39. France Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 40. France Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 41. Italy Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 42. Italy Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 43. United Kingdom Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 44. United Kingdom Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 45. Netherlands Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 46. Netherlands Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 47. Rest of Europe Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 48. Rest of Europe Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 49. MEA Multi-Dose Medication, by Country USD Million (2016-2021)
  • Table 50. MEA Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 51. MEA Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 52. Middle East Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 53. Middle East Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 54. Africa Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 55. Africa Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 56. North America Multi-Dose Medication, by Country USD Million (2016-2021)
  • Table 57. North America Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 58. North America Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 59. United States Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 60. United States Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 61. Canada Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 62. Canada Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 63. Mexico Multi-Dose Medication, by End-users USD Million (2016-2021)
  • Table 64. Mexico Multi-Dose Medication, by Software USD Million (2016-2021)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Multi-Dose Medication: by End-users(USD Million)
  • Table 76. Multi-Dose Medication Hospitals & Clinics , by Region USD Million (2022-2027)
  • Table 77. Multi-Dose Medication Pharmacies , by Region USD Million (2022-2027)
  • Table 78. Multi-Dose Medication Others , by Region USD Million (2022-2027)
  • Table 79. Multi-Dose Medication: by Software(USD Million)
  • Table 80. Multi-Dose Medication Computerized Physician Order Entry , by Region USD Million (2022-2027)
  • Table 81. Multi-Dose Medication Clinical Decision Support System , by Region USD Million (2022-2027)
  • Table 82. Multi-Dose Medication Automated Dispensing Systems , by Region USD Million (2022-2027)
  • Table 83. Multi-Dose Medication Others , by Region USD Million (2022-2027)
  • Table 84. South America Multi-Dose Medication, by Country USD Million (2022-2027)
  • Table 85. South America Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 86. South America Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 87. Brazil Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 88. Brazil Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 89. Argentina Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 90. Argentina Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 91. Rest of South America Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 92. Rest of South America Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 93. Asia Pacific Multi-Dose Medication, by Country USD Million (2022-2027)
  • Table 94. Asia Pacific Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 95. Asia Pacific Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 96. China Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 97. China Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 98. Japan Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 99. Japan Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 100. India Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 101. India Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 102. South Korea Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 103. South Korea Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 104. Australia Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 105. Australia Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 106. Rest of Asia-Pacific Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 107. Rest of Asia-Pacific Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 108. Europe Multi-Dose Medication, by Country USD Million (2022-2027)
  • Table 109. Europe Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 110. Europe Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 111. Germany Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 112. Germany Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 113. France Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 114. France Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 115. Italy Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 116. Italy Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 117. United Kingdom Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 118. United Kingdom Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 119. Netherlands Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 120. Netherlands Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 121. Rest of Europe Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 122. Rest of Europe Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 123. MEA Multi-Dose Medication, by Country USD Million (2022-2027)
  • Table 124. MEA Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 125. MEA Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 126. Middle East Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 127. Middle East Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 128. Africa Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 129. Africa Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 130. North America Multi-Dose Medication, by Country USD Million (2022-2027)
  • Table 131. North America Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 132. North America Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 133. United States Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 134. United States Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 135. Canada Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 136. Canada Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 137. Mexico Multi-Dose Medication, by End-users USD Million (2022-2027)
  • Table 138. Mexico Multi-Dose Medication, by Software USD Million (2022-2027)
  • Table 139. Research Programs/Design for This Report
  • Table 140. Key Data Information from Secondary Sources
  • Table 141. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Multi-Dose Medication: by End-users USD Million (2016-2021)
  • Figure 5. Global Multi-Dose Medication: by Software USD Million (2016-2021)
  • Figure 6. South America Multi-Dose Medication Share (%), by Country
  • Figure 7. Asia Pacific Multi-Dose Medication Share (%), by Country
  • Figure 8. Europe Multi-Dose Medication Share (%), by Country
  • Figure 9. MEA Multi-Dose Medication Share (%), by Country
  • Figure 10. North America Multi-Dose Medication Share (%), by Country
  • Figure 11. Global Multi-Dose Medication share by Players 2021 (%)
  • Figure 12. Global Multi-Dose Medication share by Players (Top 3) 2021(%)
  • Figure 13. Global Multi-Dose Medication share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Omnicell (United States) Revenue, Net Income and Gross profit
  • Figure 16. Omnicell (United States) Revenue: by Geography 2021
  • Figure 17. Epic Systems Corporation (Wisconsin) Revenue, Net Income and Gross profit
  • Figure 18. Epic Systems Corporation (Wisconsin) Revenue: by Geography 2021
  • Figure 19. BD (United States) Revenue, Net Income and Gross profit
  • Figure 20. BD (United States) Revenue: by Geography 2021
  • Figure 21. Cerner Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Cerner Corporation (United States) Revenue: by Geography 2021
  • Figure 23. McKesson Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. McKesson Corporation (United States) Revenue: by Geography 2021
  • Figure 25. UnitedHealth Group (United States) Revenue, Net Income and Gross profit
  • Figure 26. UnitedHealth Group (United States) Revenue: by Geography 2021
  • Figure 27. ARxIUM (Canada) Revenue, Net Income and Gross profit
  • Figure 28. ARxIUM (Canada) Revenue: by Geography 2021
  • Figure 29. Cureatr (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cureatr (United States) Revenue: by Geography 2021
  • Figure 31. DrFirst (United States) Revenue, Net Income and Gross profit
  • Figure 32. DrFirst (United States) Revenue: by Geography 2021
  • Figure 33. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 34. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 35. Global Multi-Dose Medication: by End-users USD Million (2022-2027)
  • Figure 36. Global Multi-Dose Medication: by Software USD Million (2022-2027)
  • Figure 37. South America Multi-Dose Medication Share (%), by Country
  • Figure 38. Asia Pacific Multi-Dose Medication Share (%), by Country
  • Figure 39. Europe Multi-Dose Medication Share (%), by Country
  • Figure 40. MEA Multi-Dose Medication Share (%), by Country
  • Figure 41. North America Multi-Dose Medication Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Omnicell (United States)
  • Epic Systems Corporation (Wisconsin)
  • BD (United States)
  • Cerner Corporation (United States)
  • McKesson Corporation (United States)
  • UnitedHealth Group (United States)
  • ARxIUM (Canada)
  • Cureatr (United States)
  • DrFirst (United States)
  • GE Healthcare (United States)
Additional players considered in the study are as follows:
Genoa (United States) , Healthcom (United States) , ICU Medical (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation